InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
81.87
(
-0.32%
)
Bitcoin
66,308.56
(
-0.50%
)
Post# of 285919
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ottoman

Send PM Follow Ignore
Followers 59
Posts 17818
Boards Moderated 1
Alias Born 03/17/2004

ottoman

Re: Buckey post# 274025

Thursday, 02/14/2019 7:45:21 AM

Thursday, February 14, 2019 7:45:21 AM

Post# of 285919
nibbled some MTFB at 2.30. -78%

http://ih.advfn.com/stock-market/NASDAQ/motif-bio-plc-MTFB/stock-news/79260777/motif-bio-receives-complete-response-letter-from-t

The CRL states that the FDA cannot approve the NDA in its present form and indicates that additional data are needed to further evaluate the risk for liver toxicity before the NDA may be approved. Motif Bio plans to request a meeting with the FDA as soon as possible to discuss potential options to address the deficiencies.

============================================================


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up